NEW YORK, March 21, 2026 (GLOBE NEWSWIRE) —
WHY: Rosen Legislation Company, a world investor rights legislation company, reminds clients of commonplace inventory of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the “Class Period”), of the necessary April 6, 2026 lead plaintiff time limit.
SO WHAT: When you bought Ultragenyx commonplace inventory right through the Magnificence Duration you can be entitled to reimbursement with out cost of any out of pocket charges or prices via a contingency price association.
WHY ROSEN LAW: We inspire traders to make a choice certified recommend with a monitor report of good fortune in management roles. Steadily, corporations issuing notices should not have similar enjoy, sources, or any significant peer popularity. Many of those corporations don’t in truth litigate securities elegance movements, however are simply middlemen that refer shoppers or spouse with legislation corporations that in truth litigate the circumstances. Be smart in deciding on recommend. The Rosen Legislation Company represents traders all through the globe, concentrating its observe in securities elegance movements and shareholder by-product litigation. Rosen Legislation Company has accomplished, at the moment, the most important ever securities elegance motion agreement towards a Chinese language Corporate. Rosen Legislation Company was once Ranked No. 1 via ISS Securities Magnificence Motion Services and products for selection of securities elegance motion settlements in 2017. The company has been ranked within the best 4 each and every yr since 2013 and has recovered loads of tens of millions of bucks for traders. In 2019 on my own the company secured over $438 million for traders. In 2020, founding spouse Laurence Rosen was once named via law360 as a Titan of Plaintiffs’ Bar. Most of the company’s lawyers had been identified via Lawdragon and Tremendous Legal professionals.
DETAILS OF THE CASE: In line with the lawsuit, defendants supplied traders with subject material data regarding Ultragenyx’s anticipated effects for its Segment III Orbit and Cosmic Research, which examined setrusumab (UX 143) in sufferers with Osteogenesis Imperfecta (“OI”). Defendants’ statements incorporated, amongst different issues, self belief in setrusumab’s skill to in the end cause a lower within the OI sufferers’ annualized fracture price, along self belief within the learn about designs to show such skill and scale back checking out variability that might intervene with this type of end result.
The lawsuit claims that defendants supplied those overwhelmingly sure statements to traders whilst concurrently disseminating materially false and deceptive statements and/or concealing subject material adversarial information regarding the actual state of setrusumab’s possible, in addition to the actual chance inherent within the learn about protocols put forth; particularly, that whilst setrusumab does build up subject material bone density, this build up does now not correlate to a lower in annualized fracture charges or differently, that the Segment III Orbit and Cosmic research had been a lot much less most probably so to show this type of hyperlink than control claimed. The lawsuit claims that such statements absent those subject material information led to Ultragenyx shareholders to buy Ultragenyx securities at artificially inflated costs. When the actual main points entered the marketplace, the lawsuit claims that traders suffered damages.
No Magnificence Has Been Qualified. Till a category is qualified, you aren’t represented via recommend until you keep one. You might make a selection recommend of your selection. You may additionally stay an absent elegance member and do not anything at this level. An investor’s skill to proportion in any possible long term restoration isn’t dependent upon serving as lead plaintiff.
Legal professional Promoting. Prior effects don’t ensure a an identical result.
——————————-
Touch Data:
